Revance Therapeutics, Inc. (RVNC) stock prices updated...
 

Revance Therapeutics, Inc. stock price

Revance Therapeutics, Inc. latest news:


  • 12/05/2017 15:21:10

    BRIEF-Revance Therapeutics Files For Potential Mixed Shelf Offering ‍​‍​

    Revance Therapeutics Inc(RVNC): * REVANCE THERAPEUTICS INC FILES FOR POTENTIAL MIXED SHELF OFFERING; SIZE NOT DISCLOSED - SEC FILING ‍​‍​ Source text: Further company coverage:

  • 12/05/2017 14:57:17

    Regal Entertainment and Revance rise; Ascena Retail slips

    Stocks that moved substantially or traded heavily Tuesday: Revance Therapeutics Inc., up $8.75 to $34.75

  • 12/05/2017 14:55:37

    BRIEF-Revance Announces Proposed Public Offering Of Common Stock

    * REVANCE THERAPEUTICS INC - PROPOSED UNDERWRITTEN PUBLIC OFFERING IN WHICH IT WILL ISSUE AND SELL APPROXIMATELY $175 MILLION OF SHARES OF ITS COMMON STOCK

  • 12/05/2017 10:16:16

    Revance stock surges and Allergan drops on positive results for wrinkle injection

    Revance Therapeutics Inc.(RVNC) shares surged nearly 38% in extremely heavy morning trade Tuesday after the company reported positive results for its wrinkle-relaxing injection in two late-stage clinical trials. If approved, the product, DaxibotulinumtoxinA for Injection, would be the first of its kind to last six months. Products currently on the market, including Allergan's (AGN) market-leading Botox, last three to four months.

  • 12/05/2017 10:16:05

    UPDATE: Revance stock surges and Allergan drops on positive results for wrinkle injection

    Revance Therapeutics Inc. shares surged nearly 38% in extremely heavy morning trade Tuesday after the company reported positive results for its wrinkle-relaxing injection in two late-stage clinical trials. If approved, the product, DaxibotulinumtoxinA for Injection (RT002), would be the first of its kind to last six months. Products currently on the market, including Allergan's market-leading Botox, last three to four months. Allergan shares dropped 3.2% in extremely heavy morning trade on Tuesday. In two trials, Revance's product showed highly statistically significant improvement relative to the placebo in reducing frown lines or wrinkles between eyebrows. The product is also being tested in a long-term safety trial, with results expected in the second half of next year; if the trial is successfully completed, Revance expects to file for approval in the first half of 2019 and, if it's approved, launch the product in the U.S. in 2020. Botox has been a wildly profitable product for Allergan, since patients largely pay out-of-pocket for it, and analysts have noted that new rivals could pose a long-term risk for the company. Revance's latest data are "better than their Ph 2 on several metrics," said EvercoreISI analyst Umer Raffat. But, with regard to being able to claim six months of effectiveness, Raffat said, "I think there's a case to be made for that, but that's not a layup." Raffat also noted that the product would likely be priced higher than Botox. In a statement to MarketWatch, Allergan called the Revance results "underwhelming." "Allergan does not expect Revance's toxin to enter the market until mid-2020, and we do not believe this data will support a longer duration claim," a company spokesperson said, adding that "based on the profile demonstrated in this data, Allergan does not view this toxin as being differentiated from Botox." Revance shares have surged 45.5% over the last three months to $35.80, compared with a 7.4% rise in the S&P 500 and a 11.7% rise in the Dow Jones Industrial Average .Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • More trends:

    Revolution Lighting Technologies, Inc.RVLT | ReWalk Robotics LtdRWLK | Rex Energy CorporationREXX | RF Industries, Ltd.RFIL | RGC Resources Inc.RGCO | RiceBran TechnologiesRIBT | RiceBran TechnologiesRIBTW | Richardson Electronics, Ltd.RELL | Rigel Pharmaceuticals, Inc.RIGL | Rightside Group, Ltd.NAME |